

[Get Access](#)[Share](#)[Export](#)

## Journal of the National Medical Association

Volume 106, Summer 2014, Pages 23-30

Original Communication

### Use of the Word “Crisis” in Sickle Cell Disease: The Language of Sickle Cell

Todd L. Savitt Ph.D. ... Melissa S. Creary M.P.H

[Show more](#)

[https://doi.org/10.1016/S0027-9684\(15\)30067-5](https://doi.org/10.1016/S0027-9684(15)30067-5)

[Get rights and content](#)

#### Abstract

Language matters. The words used to name and describe disease phenomena are a reflection of society. The authors address the use of the word “crisis” in SCD from sociological, historical, medical, and patient perspectives. The term “crisis” became associated with sickle cell disease in the mid-1920s, more than a decade after the first description of the disease had been published. The term had been used for centuries in conjunction with fever and as a signifier of severe pain in certain diseases during the nineteenth century. The application of the term to this new disease in the 1920s resulted from physicians’ observations of their patients’ urgent situations. Though commonly used by health care providers and patients today, “crisis” may not be the appropriate term for sickle cell patients suffering severe pain, because people endure differing amounts of pain before stating they are “in crisis.” The result can be undertreatment of the pain or mistrust between physicians and patients about use of strong (narcotic) pain-relievers. Some patients believe the term is useful in communicating the severity of their pain and the urgency of their need for relief from it, especially when seeking care at hospital emergency departments, while others believe “crisis” does not accurately reflect the severity or seriousness of their situation.

[Previous](#)[Next](#)

#### Keywords

sickle cell disease; crisis; history; pain

[Recommended articles](#)

[Citing articles \(0\)](#)

**Financial disclosures:** Creary and Savitt received no funding or sponsorship in the development of this submission. Smith was supported in part by funding from: Virginia Basic and Translational Research Program in Sickle Cell Disease. 1U54HL090516, National Heart, Lung, and Blood Institute; Sickle Cell Disease Clinical Research Network, National Heart, Lung, and Blood Institute 1U10HL083732; Pain in Sickle Cell Epidemiology Study, 1 R01 HL 64122, National Heart, Lung, and Blood Institute, NIH. Haywood was supported by a Career Development Award from the National Heart, Lung, and Blood Institute (#1K01HL108832-01).

**Acknowledgement:** The authors acknowledge the assistance of Mr. T.J. Brown, President of the Sickle Cell Natural Wellness Group, Broward County, Florida, in collecting and compiling the patient information from a survey conducted on his website, <http://sicklecellcantstopme.wix.com/sickle-cell-natural-wellness-group-inc#!>

**ELSEVIER** [About ScienceDirect](#) [Remote access](#) [Shopping cart](#) [Contact and support](#) [Terms and conditions](#) [Privacy policy](#)

We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the [use of cookies](#).

Copyright © 2018 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.

 **RELX** Group™